PARP1 and COVID-19: Interestingly, SARS-CoV-2 has been linked to various members of the PARP [poly (ADP)-ribose polymerase] family and PARP inhibitors, such as stenoparib or olaparib, have been suggested as anti-COVID-19 agents [197–199].